The clinical importance of these pathways is highlighted by emerging therapeutic strategies aimed at blocking NKG2A (e.g. monalizumab) or the PD-1/PD-L1 axis, which have shown promising results in restoring NK and T cell tumor surveillance [135–137]. This evidence concerns the gene PDCD1 and neoplasm.